Hot Investor Mandate: USA Family Office Seeks Worldwide Opportunities in Medical Technology and Consumer Health

~ Next Phase Admin ~ Leave a comment

This family office is an investment fund associated with an industrial engineering firm. The firm invests in and incubates new technologies in the medical device and consumer health sectors. The firm is highly flexible in terms of investment structure, focusing on opportunities in which their engineering and commercialization expertise can provide a value-add. The firm’s investments may include equity financing, services such as prototyping and design, and other structures such as royalties. The firm will invest worldwide.

The family office focuses on medical technology and consumer health, including devices, diagnostics, sterilization, blood testing, sensors, MRI/Radiation machines, and home health products. The firm is a multi-stage investor, and has worked with entrepreneurs as early as idea-stage. The firm invests in all classes of medical device including PMA opportunities.

The family office is focused on investing in companies in which the firm’s expertise is a relevant value-add.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Arm of Hong Kong Family Office Actively Invests in Therapeutics, Medical Device, Diagnostics Startups and Healthcare Services with Strong China Market Potential

~ Next Phase Admin ~ Leave a comment

A venture arm of an investment firm founded by a family office in Hong Kong is focused on making early stage life science investments across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and more. The firm is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.

The firm seeks to invest in new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc. For therapeutics, the firm seeks novel small molecule and biologics and is agnostic in terms of indication. However, indications that address a large market in China are of interest. The firm looks for early stage assets in pre-clinical and phase I of clinical trials. However, the firm will not rule out assets in phase II. For devices, the firm is opportunistic in terms of the class of device.

The firm seeks an active role in its portfolio companies and generally obtain a seat on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: UK-Based Private Investment Firm Seeks Therapeutics Companies with Particular Interest in Metabolic Diseases, Immunology, Aging and Infectious Diseases Indications

~ Next Phase Admin ~ Leave a comment

A private life science investment firm has a presence in U.K, Canada and multiple locations in U.S. The firm looks to make investments into privately held companies and while the firm can be flexible in terms of allocation size, most investments fall in the $0.5 – 3 million range. The firm is open to investing in companies located around the globe.

The firm is currently looking for therapeutics companies across all indication areas with particular attention to metabolic diseases (including type II diabetes), immune-oncology, aging, and infectious diseases. The firm is interested in pre-clinical stage companies that have a lead asset established as well as companies in early clinical trials. The firm is open to all molecule types that meet this criteria. The firm is generally not interested in next generation cytotoxic chemotherapies, therapies for Alzheimer’s Disease, or therapies for cardiovascular indications.

The firm is a hands-on investor who contribute substantially to the operation of their portfolio companies, often supplementing management with a network of drug developers and specialists in regulatory affairs, clinical affairs, manufacturing, and other subspecialties.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based, US-Specialized VC Seeks Opportunities in Early Stage to Pre-IPO Across All Life Science & Healthcare Industries

~ Next Phase Admin ~ Leave a comment

A specialized US venture capital firm under a holding group company focuses on finance, conducting business with its Chinese sister company as one group. The firm has headquarters in China and an additional virtual office in the U.S. The firm is actively seeking investment opportunities from early stage to pre-IPO rounds. The average size of investment is ~ $5M. The firm has invested in 17 US & Canada companies since 2016. The firm can act as the lead investor or co-investor depends on different cases, and the firm prefers to have a board seat.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics. The firm will also consider orphan drugs and digital health companies. The firm is open to all kinds of sectors. The firm is open to medical devices with all FDA regulatory pathways, including 510k and PMA. The firm is open to any phases in medical devices and therapeutics. However, the firm will invest in private companies only.

The firm has no specific requests on the management team. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Here’s The Plan: It Pays To Go Digital, ‘Till June

~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

LSN had to pivot a few weeks ago and create Digital RESI Global Conference. The site remains open and anyone can see the gist of what LSN did on this “live” page. LSN could do this because we have done over 30 physical conferences and never outsourced any part of the conference except the 3rd party partnering software, to which we added a “matching module” that is unique to LSN. Because we had done our own program guides in the past, we had a lot of the formatting issues conquered for the digital version.  The difficulty at any event is the staff chasing down all the content for the program guide, including speaker bios, marketing collateral and company profiles etc. Always down to the wire.

Digital RESI Global doubled our predicted attendee turnout with investment partners and fundraising CEOs. The metrics are actually quite interesting and surprised us in revealing the pent up demand for action in the life science arena in these troubled times.  Partnering led the way and Panels, Workshops and Company Presentations did remarkably well. I never would have thought that these troubled times would have contributed to a new model that seems to be shifting the paradigm.

Life Science Nation & Women In Bio Join Forces to Feature Women In Bio Members at RESI

~ Next Phase Admin ~ Leave a comment

By Erich White, Business Development Manager, West Coast, LSN

LSN is pleased to announce that Women In Bio will be joining the RESI Conference Series as a Gold Sponsor for both the Digital RESI partnering event on April 29-30, and Digital RESI conference, June 8-10. Women In Bio plays a vital role in the life sciences, ensuring women founders and first time CEOs have the resources and support needed to grow successful bioscience-related businesses, and providing a forum for women to come together to celebrate and support each other’s success. WIB is partnering with LSN to connect women leading early stage life science companies with global investors and strategic partners. WIB will also sponsor a pitch session during the Digital RESI conference in June, featuring 5 WIB-member companies.

Women In Bio – Engage. Educate. Empower.

Women in Bio/WIB is a US non-profit organization founded in 2002 to support and connect women in the life sciences from the classroom to the board room.

We are an organization of professional women from all career walks in the field of life sciences. We are all volunteers and we all share the goal of enabling and empowering women to reach the highest levels of leadership, and — more importantly — to fulfill their own career aspirations.

We belong to biotech and pharma companies, universities and institutes, law and accounting firms, marketing and PR firms, CROs and CMOs.

WIB’s primary focus is to provide women-to-women mentorship and leadership support through all stages of career development

  • from bench to boardroom
  • from academia to industry
  • from first job to last
  • from idea to entrepreneur

With 13 chapters in the US and Canada WIB is committed to fulfill this mission with educational webinars, events, mentoring and networking.

Some of the well-recognized programs are:

Young Women in Bio with STEM education, Executive Women in Bio with the Board Room Ready program.

Many of our members are entrepreneurs, and a focus on entrepreneurship has remained core to WIB’s mission.

With the WIB-Entrepreneur Center we started an entrepreneur focused program dedicated to supporting female founders and first time CEOs from early start-up to later project stages of their life science companies. Besides offering resources, educational webinars as well as mentoring, we engage women founders/CEOs in peer to peer forums and work on the most critical need which is access to capital and corporate partnerships by offering this year in June a Women In Bio sponsored virtual Pitch Challenge in partnership with Life Science Nation (LSN)/RESI.

Hot Investor Mandate: USA-Based VC Firm Invests Up to $30M in Therapeutics, Diagnostics, R&D Tools, Seeking Globally

~ Next Phase Admin ~ Leave a comment

A venture capital firm based in the USA currently manages a $500M fund dedicated to life science investments. The firm can invest anywhere from $4-30M and invests in both seed and crossover rounds. While most of the current portfolio companies are USA-based, the firm has a global portfolio and is open to global investment opportunities.

The firm focuses on these 3 key areas: therapeutics, diagnostics, and R&D tools/services. The firm also considers digital health opportunities that tie in with their key areas, such as technologies enhancing R&D efficacy, drug development process, etc. The firm stirs away from medical devices (basically, all technologies that require FDA approval), including implantable devices. With regards to the firm’s main interest areas, The firm is most interested in seeing new approaches (i.e. cell & gene therapy, novel ways of manufacturing cell lines, etc). The firm will invest in both pre-clinical and clinical technologies.

The firm has no specific company or management team requirements and is open to working with management teams coming from varying levels of experience. The firm prefers to act as the lead investor, and has done so for almost all of their portfolio companies thus far. The firm is a very active, hands-on investor and will generally seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.